Serum Adipokines Associated With Diabetic Risk Factors
By LabMedica International staff writers Posted on 10 Jan 2012 |
Cytokines produced by the adipose tissue are known as adipokines and abnormal levels in the serum maybe cardiovascular risk factors for diabetic patients.
The relationship of the serum profile of adipokines, such as leptin, adiponectin, resistin, and interleukin 6 (IL-6) has been evaluated with these risk factors for obese patients with diabetes mellitus type 2 (DM2).
In a prospective study at the University of Valladolid (Spain), 108 obese patients with DM2 were enrolled and their blood was analyzed. A complete biochemical, anthropometric, and nutritional evaluation was performed. Basal glucose, C-reactive protein (CRP), insulin, total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density liporotein (HDL)-cholesterol, triglycerides blood, and adipokines (leptin, adiponectin, resistin, and IL-6) levels were measured in fasting condition.
Interleukin 6 was measured by an enzyme-linked immunosorbent assay ELISA (R&D systems, Inc.; Minneapolis, MN, USA) with a sensitivity of 0.5 pg/mL. Normal values of IL6 were 1.12-12.5 pg/mL. Adiponectin was measured by an ELISA, also from R&D systems, with a sensitivity of 0.246 ng/mL and a normal range of 865-21,424 ng/mL. Resistin was measured by an ELISA (Biovendor Laboratory, Inc.; Brno, Czech Republic) with a sensitivity of 0.2 ng/mL and a normal range of 4-12 ng/mL. Leptin was measured by ELISA (Diagnostic Systems Laboratories, Inc.; Webster, TX, USA) with a sensitivity of 0.05ng/mL and a normal range of 10-100 ng/mL.
The authors concluded that the serum profile of adipokines is related with different cardiovascular risk factors and anthropometrical variables in obese patients with diabetes type 2. The serum profile of the adipokines showed that only leptin levels were higher in women than in men. These associations have different implications with each adipokine and each parameter was shown by multivariate analysis. The study was published in the November 2011 issue of Journal of Clinical Laboratory Analysis .
Related Links:
University of Valladolid
R&D systems
Biovendor Laboratory
The relationship of the serum profile of adipokines, such as leptin, adiponectin, resistin, and interleukin 6 (IL-6) has been evaluated with these risk factors for obese patients with diabetes mellitus type 2 (DM2).
In a prospective study at the University of Valladolid (Spain), 108 obese patients with DM2 were enrolled and their blood was analyzed. A complete biochemical, anthropometric, and nutritional evaluation was performed. Basal glucose, C-reactive protein (CRP), insulin, total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density liporotein (HDL)-cholesterol, triglycerides blood, and adipokines (leptin, adiponectin, resistin, and IL-6) levels were measured in fasting condition.
Interleukin 6 was measured by an enzyme-linked immunosorbent assay ELISA (R&D systems, Inc.; Minneapolis, MN, USA) with a sensitivity of 0.5 pg/mL. Normal values of IL6 were 1.12-12.5 pg/mL. Adiponectin was measured by an ELISA, also from R&D systems, with a sensitivity of 0.246 ng/mL and a normal range of 865-21,424 ng/mL. Resistin was measured by an ELISA (Biovendor Laboratory, Inc.; Brno, Czech Republic) with a sensitivity of 0.2 ng/mL and a normal range of 4-12 ng/mL. Leptin was measured by ELISA (Diagnostic Systems Laboratories, Inc.; Webster, TX, USA) with a sensitivity of 0.05ng/mL and a normal range of 10-100 ng/mL.
The authors concluded that the serum profile of adipokines is related with different cardiovascular risk factors and anthropometrical variables in obese patients with diabetes type 2. The serum profile of the adipokines showed that only leptin levels were higher in women than in men. These associations have different implications with each adipokine and each parameter was shown by multivariate analysis. The study was published in the November 2011 issue of Journal of Clinical Laboratory Analysis .
Related Links:
University of Valladolid
R&D systems
Biovendor Laboratory
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms